Charles River (NYSE: CRL) raises 2026 guidance, but a tax gain drives GAAP EPS

What happened

Charles River Laboratories International, Inc. (NYSE: CRL) raised its 2026 revenue and non-GAAP earnings guidance on Nov. 4 after a stronger third quarter.

Third-quarter revenue was $982.7 million, down 2.2% from $1.00 billion a year earlier, mainly because of the May 2026 divestitures. Organic revenue, which leaves out acquisitions, divestitures and currency translation, rose 4.7%. The company called it a return to organic growth for the second straight quarter.

GAAP earnings per share were $6.86, against $1.10 in the third quarter of 2025. Non-GAAP earnings per share were $3.09, up 27.2% from $2.43. Non-GAAP operating margin widened 330 basis points to 23.0%. GAAP operating margin widened 730 basis points to 20.6%.

Key numbers

Metric	Latest	Change	Source
Third-quarter revenue	$982.7 million	from $1.00 billion, -2.2%	SEC 8-K, Exhibit 99.1
Organic revenue growth	+4.7%		SEC 8-K, Exhibit 99.1
GAAP diluted EPS	$6.86	from $1.10	SEC 8-K, Exhibit 99.1
Non-GAAP diluted EPS	$3.09	from $2.43, +27.2%	SEC 8-K, Exhibit 99.1
Non-GAAP operating margin	23.0%	from 19.7%, +330 basis points	SEC 8-K, Exhibit 99.1
2026 non-GAAP EPS guidance (midpoint change)	$11.35 to $11.55	+$0.15	SEC 8-K, Exhibit 99.1

Read more: Charles River Laboratories International (CRL) company research

Where the GAAP profit came from

A one-time tax item drives the GAAP figure. Charles River booked a benefit of $245.6 million, or $5.06 per share. It came from reversing acquired tax reserves after new tax legislation and the completion of certain tax requirements in a foreign jurisdiction. By OptimistFi's calculation, that benefit equals 73.8% of the quarter's GAAP earnings per share.

GAAP operating margin also includes a $44.6 million benefit in the Discovery and Safety Assessment (DSA) segment. It came from reversing acquired non-income tax reserves.

Non-GAAP results exclude those items. Non-GAAP net income was $150.1 million, up 24.8% from $120.3 million. The company credits the rise mainly to the higher operating margin and a lower tax rate, so tax also helped the adjusted figure.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

How the three segments performed

DSA revenue was $596.3 million, down 0.7% from $600.7 million, after the sale of certain European Discovery Services sites. Organic revenue rose 5.9% on higher study volume for regulated safety assessment services. Non-GAAP operating margin rose to 26.8% from 25.4%, on operating leverage from that volume and lower sourcing costs for large research models.

Manufacturing Solutions revenue fell 6.2% to $178.9 million from $190.7 million because of the CDMO divestiture. Organic revenue rose 7.4% on demand in Biologics Testing Solutions and Microbial Solutions. Its non-GAAP margin jumped to 38.6% from 26.7%. The company credits that mainly to the CDMO divestiture.

Research Models and Services revenue slipped 2.8% to $207.5 million from $213.5 million on the Cell Solutions divestiture. Organic revenue fell 0.6%, mainly on lower small research model revenue in North America and lower large research model revenue. Non-GAAP margin eased to 24.4% from 25.0% on an unfavorable revenue mix.

Why it matters

OptimistFi has argued that Charles River is a margin-recovery and outsourcing-durability story. The stock works only if the earnings collapse proves cyclical rather than structural. The quarter backs the operating side of that view. DSA organic growth came from higher regulated study volume, and CEO Birgit Girshick said DSA net bookings and proposals continued to show year-over-year increases.

The support is partial. Reported revenue still fell, and the Manufacturing margin gain came mainly from the divestiture rather than from demand. The headline GAAP profit rests on a tax reversal, and a lower tax rate lifted non-GAAP earnings too. Research Models and Services organic revenue also declined. OptimistFi reads the quarter as mixed for the case.

Cash flow adds a second check. Operating cash flow for the first nine months was $474.9 million, down from $590.1 million a year earlier. Long-term debt, net and finance leases stood at $2.44 billion on Sept. 26, up from $2.14 billion on Dec. 27, 2025. The company spent $324.1 million on treasury stock in the nine months.

What the raised guidance says

Charles River now expects reported 2026 revenue to decline 1.5% to 2.0%. The prior range was a decline of 2.5% to 3.5%. Organic revenue is guided to grow at least 1.5%, up from 0.0% to 1.0%, an increase of 100 basis points.

Non-GAAP earnings per share guidance is $11.35 to $11.55, up from $11.15 to $11.45, a $0.15 rise at the midpoint. GAAP guidance is $8.15 to $8.35, up from $3.05 to $3.35, mainly because of the third-quarter tax reserve reversal. The company says the increases mostly reflect third-quarter outperformance in DSA and a lower tax rate.

What's next

Charles River scheduled a live webcast for Wednesday, Nov. 4, at 9:00 a.m. ET to discuss the results.

The next quarterly report is the cleaner test. Organic growth at or above the raised full-year floor, with margins intact and no tax reversal in the numbers, would support the cyclical reading. Slower DSA organic growth or a lower non-GAAP operating margin would weaken it.

More from OptimistFi

• CRL stock: research and coverage of Charles River Laboratories International
• Stock research on every company OptimistFi covers

From OptimistFi Perps